SK Bioscience participates in supply of COVID-19 vaccine

The MOHW-AZ-SK Bioscience signed LOI

A domestic pharmaceutical bio company has been recognized for its production technology and has joined the world development leader multinational companies and the global production supply chain of COVID-19 vaccine.

 

The government is trying to supply domestically some of the vaccines produced in Korea.

 

The MOHW (Minister Park Neunghoo), today (21st) at 4 pm at the SK Bioscience Research Institute (Seongnam Pangyo), with AstraZeneca (CEO Pascal Soriot) and SK Biosciences (CEO Ahn Jae-yong), The AstraZeneca-Jenner Institute (University of Oxford) has signed a Letter of Intent (LOI) for a global supply of vaccine candidates under development and cooperation in securing domestic supplies.

 

According to the World Health Organization (WHO), the vaccine being developed by the AstraZeneca-Zener Institute is currently attracting attention from around the world as one of the most likely vaccines to enter Phase III of COVID-19 vaccine candidates.

 

The vaccine has been in Phase III clinical trials in the UK, Brazil and South Africa since June.

 

AstraZeneca and SK Biosciences have been participating in discussions as partners for global manufacturing and production.

 

And the government explained that the result was achieved by signing LOI ( a Letter Of Intent) today.

 

The signing ceremony for this LOI was attended by Minister Park Neunghoo, British Ambassador to the Republic of Korea Simon Smith, CEO Sang-Pyo Kim of AstraZeneca Korea, The vice president of SK Discovery Chey Chang-won , and SK Bioscience chief Ahn Jae-yong, It was conducted by the participation of AstraZeneca Global Chief Executive Officer (CEO) Pascal Soriot participated in the video conference.

 

LOI included ▲ fast and stable production and export cooperation for the fair global supply of vaccines ▲ strengthened production capacity to respond to increasing demand ▲ domestic supply efforts, and three-way cooperation.

 

The government explained that this is the first time that a domestic company has joined the global supply chain of excellent vaccines, which is gaining global attention, for the first time.

 

The MOHW will continue to discuss that some of the vaccines produced by SK Biosciences will be supplied to Korea.

 

It is expected to be a representative example of cooperation between the government and companies in the global epidemic of infectious diseases, in that it will secure a stable supply and demand system for successful vaccine development.

 

The government will continue to pursue two-track strategy centered on the 'COVID-19 Treatment and Vaccine Development Support Committee,' which will continue to be shared by related ministries, and will continue to provide support for domestic companies' own vaccine development, as well as the rapid acquisition of overseas vaccines that are rapidly developing.

 

At the signing ceremony, Minister Park said, "We are proud that Korean technology can contribute to the production of vaccines that are supplied to the world, and it is also a great achievement to establish a preemptive domestic supply and demand system," He also added, "The Korean government will also actively participate in the international community's solidarity efforts to ensure equitable distribution and accessibility since the development of the vaccine."